Compumedics Ltd (ASX:CMP) chairman Dr David Burton and CFO David Lawson speak with Proactive following news the US Food & Drug Administration (FDA) has cleared the company’s Somfit device to be marketed in the USA. They say it marks the achievement of another significant strategic milestone for the Somfit technology platform in one of the world’s largest sleep markets. The home sleep testing (HST) market in the USA, which the Somfit is primarily targeted at, is estimated to be about two million studies per year.
Compumedics welcomes FDA clearance for Somfit
